Aliskiren/hydrochlorothiazide
| Combination of | |
|---|---|
| Aliskiren | Renin inhibitor |
| Hydrochlorothiazide | Diuretic |
| Clinical data | |
| Trade names | Tekturna HCT, Rasilez HCT, others |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Aliskiren/hydrochlorothiazide, sold under the brand name Tekturna HCT among others, is a
fixed-dose combination medication for the treatment of hypertension (high blood pressure).[1][2][3][4] It contains aliskiren, a renin inhibitor, and hydrochlorothiazide, a diuretic.[1][2] It is taken by mouth.[1]
The most common side effect is diarrhea.[2]
Aliskiren/hydrochlorothiazide was approved for medical use in the United States in January 2008,[5] and for use in the European Union in January 2009.[2]
Medical uses
Aliskiren/hydrochlorothiazide is
indicated for the treatment of essential hypertension in adults.[2]
References
- ^ a b c d "Tekturna HCT- aliskiren hemifumarate and hydrochlorothiazide tablet, film coated". DailyMed. 7 January 2020. Retrieved 26 August 2020.
- ^ a b c d e f "Rasilez HCT EPAR". European Medicines Agency. 17 September 2018. Retrieved 27 August 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- S2CID 44410886.
- PMID 19337534.
- ^ "Drug Approval Package: Tekturna HCT (aliskiren/hydrochlorothiazide) NDA #022107". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 27 August 2020.
- Lay summary in: "Center for Drug Evaluation and Research: Application Number: 22-107: Summary review" (PDF). U.S. Food and Drug Administration (FDA).
External links
- "Aliskiren hemifumarate mixture with hydrochlorothiazide". Drug Information Portal. U.S. National Library of Medicine.
